Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

BACKGROUND: Preclinical data suggest cell cycle checkpoint blockade may induce an immunostimulatory tumor microenvironment. However, it remains elusive whether immunomodulation occurs in the clinical setting. To test this, we used blood and fresh tissue samples collected at baseline and post therapy...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Lampert, Erika J, Cimino-Mathews, Ashley, Lee, Joo Sang, Nair, Jayakumar, Lee, Min-Jung, Yuno, Akira, An, Daniel, Trepel, Jane B, Ruppin, Eytan, Lee, Jung-Min
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Clinical/Translational Cancer Immunotherapy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7380948/
https://ncbi.nlm.nih.gov/pubmed/32709712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000516
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky